Results 121 to 130 of about 243,338 (243)

Physiological Monitoring Applications of Wearable Multimodal Fusion Systems Based on ECG and PPG: A Comprehensive Review. [PDF]

Sensors (Basel)
Rathnayake C, Chen W, Jayawickrama S, Lai D.   +3 more
europepmc   +1 more source

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran, Naihan Chen, Jennifer A. Winton, Kyle T. Matschke, Smita P. Goodman, Kimberly C. Lee, Yuanyuan Zhang, Weiwei Tan   +7 more
wiley   +1 more source

A Case of Clinically Suspected Kounis Syndrome Associated with Platelet Transfusion during Thoracoscopic Right Lower Lobectomy. [PDF]

Surg Case Rep
Baba T, Inokawa H, Okada M, Okita R.
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source

AI-ECG for Echocardiography Triage in Structural Heart Disease: Evidence, Implementation, and Future Directions. [PDF]

Int J Gen Med
Tang Q, Deng K, Cui Y, Liu H, Qian B.
europepmc   +1 more source

Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies, Elin Haf Davies, Dyfrig A. Hughes   +2 more
wiley   +1 more source

AI-Powered Resting 12-Lead Electrocardiogram Algorithm for Predicting Low Peak Oxygen Consumption: Development and Validation Study. [PDF]

JMIR Med Inform
Huang SC, Fu TC, Liou M, Huang YC, Chang SY, Huang GY, Su HR, Su HR.   +7 more
europepmc   +1 more source

Glycopolymeric nanoparticles transported by activated platelets protect ischemic myocardium by alleviating PANoptosis through targeting macrophage Dectin‐1

BMEMat, EarlyView.
NP‐SF, designed to target macrophage Dectin‐1 and activated platelets, selectively accumulated in ischemic myocardium, where it was taken up by macrophages after platelet hitchhiking. By inhibiting NLRC5‐related PANoptosis, NP‐SF significantly attenuated pathological damage, and effectively preserved cardiac function in a murine ischemia–reperfusion ...
Guanye Yu, Na Yang, Yan Zhang, Lingxin Peng, Yi Li, Yue Chao, Qinfang Miao, Haikun Qi, Jianhui Zhuang, Weixia Jian, Bingyu Li, Wenhui Peng, Jinghua Chen, Shiyu Gong   +13 more
wiley   +1 more source